Hoxworth Blood Center welcomes new chief financial officer/executive doctor of business administration
Hoxworth Blood Center, University of Cincinnati, is pleased to announce the appointment of new chief financial officer/executive doctor of business administration (CFO/EDBA), Nick Leibold, MBA.
Leibold comes to Hoxworth after a financial career in highly prestigious investment, financial and pharmaceutical corporations in New York and work as a successful chief financial officer and co-chief executive officer of a pharmaceutical company with employees and operations across 40+ states.
“Mr. Leibold’s expertise will help us support and strengthen the services we provide to patients and donors in the Tri-State,” states Hoxworth director, José Cancelas, MD, PhD. “He brings many attributes to the senior leadership of Hoxworth and will play a key role in our strategic efforts going forward.”
Leibold, a Cincinnati native, earned his B.S. in Finance from Miami University and his MBA from the Stern School of Business of New York University.
Hoxworth Blood Center welcomed Leibold’s arrival on March 27, 2023.
Related Stories
UC experts present neurology research at national conference
April 17, 2026
University of Cincinnati researchers will present abstracts at the 2026 American Academy of Neurology Annual Meeting April 18 to 22 in Chicago.
Health care industry is hiring despite a job market that has cooled
April 16, 2026
The US labor market has cooled but the demand for health care workers, expecially skilled nurses, remains strong. Interviews with UC College of Nursing admininstrators Dr. Donna Green and Dr. Lindsay Davis were part of a WCPO segment on health care industry hiring.
AI advances in the liver disease field
April 15, 2026
MASH represents the advanced inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease), where fat accumulation in the liver triggers fibrosis and progressive liver injury. According to a recent MedCentral article, more AI-based clinical assessment tools in MASH are needed.